Apollo Endosurgery (APEN) 10-Q 3 May 22 2022 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2022	Apr. 29, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-35706
Entity Registrant Name	APOLLO ENDOSURGERY, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	16-1630142
Entity Address, Address Line One	1120 S. Capital of Texas Highway
Entity Address, Address Line Two	Building 1, Suite #300
Entity Address, City or Town	Austin
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	78746
City Area Code	512
Local Phone Number	279-5100
Title of 12(b) Security	Common stock, par value $0.001 per share
Trading Symbol	APEN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		40,250,402
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001251769
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 81,730	$ 90,691
Accounts receivable, net of allowance for doubtful accounts of $345 and $330, respectively	11,066	10,078
Inventory	13,251	11,966
Prepaid expenses and other current assets	2,451	1,965
Total current assets	108,498	114,700
Restricted cash	1,008	1,121
Property, equipment and right-of-use assets, net	5,768	5,593
Goodwill	5,290	5,290
Intangible assets, net of accumulated amortization of $14,948 and $14,814, respectively	4,028	4,400
Other assets	423	424
Total assets	125,015	131,528
Current liabilities:
Accounts payable	6,396	4,584
Accrued expenses	7,556	9,902
Total current liabilities	13,952	14,486
Long-term debt	33,594	33,473
Convertible debt	19,563	19,513
Long-term liabilities	2,873	2,819
Total liabilities	69,982	70,291
Commitments and contingencies
Stockholders’ equity:
Common stock; $0.001 par value; 100,000,000 shares authorized; 40,102,879 and 39,546,323 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively	40	40
Additional paid-in capital	358,717	356,516
Accumulated other comprehensive income	2,145	2,136
Accumulated deficit	(305,869)	(297,455)
Total stockholders’ equity	55,033	61,237
Total liabilities and stockholders’ equity	$ 125,015	$ 131,528

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 345	$ 330
Accumulated amortization	$ 14,948	$ 14,814
Common stock, par value (USD per share)	$ 0.001	$ 0.001
Common stock, shares authorized (shares)	100,000,000	100,000,000
Common stock, shares issued (shares)	40,102,879	39,546,323
Common stock, shares outstanding (shares)	40,102,879	39,546,323

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Revenues	$ 16,662	$ 13,857
Cost of sales	7,289	6,350
Gross margin	9,373	7,507
Operating expenses:
Sales and marketing	8,220	4,790
General and administrative	5,231	4,069
Research and development	2,713	1,928
Amortization of intangible assets	456	474
Total operating expenses	16,620	11,261
Loss from operations	(7,247)	(3,754)
Other (income) expenses:
Interest expense, net	1,222	1,352
Other income, net	(242)	(564)
Net loss before income taxes	(8,227)	(4,542)
Income tax expense	187	59
Net loss	(8,414)	(4,601)
Other comprehensive (loss)/income:
Foreign currency translation	9	(885)
Comprehensive loss	$ (8,405)	$ (5,486)
Net loss per share, basic (USD per share)	$ (0.21)	$ (0.17)
Net loss per share, diluted (USD per share)	$ (0.21)	$ (0.17)
Shares used in computing net loss per share, basic (shares)	39,652,299	26,306,442
Shares used in computing net loss per share, diluted (shares)	39,652,299	26,306,442

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders’ Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2020		25,819,329
Beginning balance at Dec. 31, 2020	$ 6,751	$ 26	$ 276,569	$ 2,929	$ (272,773)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of common stock options (in shares)		21,493
Exercise of common stock options	60		60
Exercise of common stock warrants (in shares)		999,855
Exercise of common stock warrants	0	$ 1	(1)
Issuance of restricted stock and performance stock units (in shares)		11,337
Issuance of common stock for convertible debt interest (in shares)		161,184
Issuance of common stock for convertible debt interest	572		572
Conversion of convertible debt (in shares)		22,644
Conversion of convertible debt	74		74
Stock-based compensation	720		720
Foreign currency translation	(885)			(885)
Net loss	(4,601)				(4,601)
Ending balance (in shares) at Mar. 31, 2021		27,035,842
Ending balance at Mar. 31, 2021	$ 2,691	$ 27	277,994	2,044	(277,374)
Beginning balance (in shares) at Dec. 31, 2021	39,546,323	39,546,323
Beginning balance at Dec. 31, 2021	$ 61,237	$ 40	356,516	2,136	(297,455)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of common stock options (in shares)		8,216
Exercise of common stock options	32		32
Exercise of common stock warrants (in shares)		450,842
Issuance of restricted stock and performance stock units (in shares)		21,718
Issuance of common stock for convertible debt interest (in shares)		75,780
Issuance of common stock for convertible debt interest	613		613
Conversion of convertible debt	0
Stock-based compensation	1,556		1,556
Foreign currency translation	9			9
Net loss	$ (8,414)				(8,414)
Ending balance (in shares) at Mar. 31, 2022	40,102,879	40,102,879
Ending balance at Mar. 31, 2022	$ 55,033	$ 40	$ 358,717	$ 2,145	$ (305,869)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (8,414)	$ (4,601)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	741	904
Amortization of deferred financing costs	113	133
Non-cash interest	486	446
Provision for doubtful accounts receivable	26	(18)
Stock-based compensation	1,556	720
Unrealized foreign exchange on intercompany payables	(315)	(545)
Changes in operating assets and liabilities:
Accounts receivable	(947)	(1,443)
Inventory	(1,279)	(236)
Prepaid expenses and other assets	(403)	(347)
Accounts payable and accrued expenses	(253)	678
Net cash used in operating activities	(8,689)	(4,309)
Cash flows from investing activities:
Purchases of property and equipment	(467)	(221)
Purchases of intangibles and other assets	(84)	(76)
Net cash used in investing activities	(551)	(297)
Cash flows from financing activities:
Proceeds from exercise of stock options	32	60
Net cash provided by financing activities	32	60
Effect of exchange rate changes on cash	134	(6)
Net change in cash, cash equivalents and restricted cash	(9,074)	(4,552)
Cash, cash equivalents and restricted cash at beginning of year	91,812	37,200
Cash, cash equivalents and restricted cash at end of period	82,738	32,648
Supplemental disclosure of cash flow information:
Cash paid for interest	410	775
Cash paid for income taxes	(8)	4
Right-of-use assets recognized in exchange for lease obligations (non-cash)	107	0
Issuance of common stock for convertible debt interest (non-cash)	613	572
Issuance of common stock from conversion of convertible debt (non-cash)	$ 0	$ 74

Organization and Business Descr

Organization and Business Description	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Description	Organization and Business Description Apollo Endosurgery, Inc. is a Delaware corporation with both domestic and foreign wholly-owned subsidiaries. Throughout these Notes, “Apollo” and the “Company” refer to Apollo Endosurgery, Inc. and its consolidated subsidiaries. Apollo is a medical technology company primarily focused on the development of next-generation, less invasive medical devices to advance gastrointestinal therapeutic endoscopy. The Company develops and distributes devices that are used by surgeons and gastroenterologists for a variety of procedures related to gastrointestinal conditions including closure of gastrointestinal defects, managing gastrointestinal complications and the treatment of obesity. The Company’s core products include the OverStitch® Endoscopic Suturing System, the OverStitch Sx® Endoscopic Suturing System, X-Tack® Endoscopic HeliX Tacking System (collectively “ESS”) and the ORBERA® Intragastric Balloon (“IGB”). All devices are regulated by the U.S. Food and Drug Administration (the “FDA”) or an equivalent regulatory body outside the U.S. The Company has offices in the United Kingdom and Italy that oversee commercial activities outside the U.S. and a products manufacturing facility in Costa Rica. All other activities are managed and operated from facilities in Austin, Texas.

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Significant Accounting Policies	Significant Accounting Policies (a) Basis of Presentation The Company prepared its interim condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). They do not include all of the information and footnotes required by GAAP for complete financial statements. The accompanying condensed consolidated financial statements include the Company’s accounts and the accounts of its wholly-owned subsidiaries. The Company has eliminated all intercompany balances and transactions. The Company has made estimates and judgments affecting the amounts reported in its condensed consolidated financial statements and the accompanying notes. The actual results that the Company experiences may differ materially from the Company’s estimates. The accounting estimates that require the Company’s most significant, difficult and subjective judgments include revenue recognition and inventory valuation. (b) Unaudited Interim Results In management’s opinion, the unaudited financial information for the interim periods presented includes all adjustments necessary for a fair presentation of the results of operations, financial position, and cash flows. All adjustments are of a normal recurring nature unless otherwise disclosed. Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be the same as those for the full year. This interim information should be read in conjunction with the audited consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. (c) Recent Accounting Pronouncements In August 2020, Accounting Standards Update (“ASU”) No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity was issued, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. This ASU will become effective for the Company on January 1, 2024 and is not expected to have a material impact on the consolidated financial statements. In May 2021, ASU No. 2021-04, Issuer’s Accounting for Certain Modifications of Exchanges of Freestanding Equity-Classified Written Call Options

Concentrations

Concentrations	3 Months Ended
	Mar. 31, 2022
Risks and Uncertainties [Abstract]
Concentrations	ConcentrationsConsolidated financial instruments that potentially subject the Company to a concentration of credit risk principally consist of cash and cash equivalents and accounts receivable. At March 31, 2022, the Company’s cash, cash equivalents and restricted cash are held in deposit accounts at four different banks totaling $82,738. The Company has not experienced any losses in such accounts, and management does not believe the Company is exposed to any significant credit risk. Management further believes that credit risk in the Company’s accounts receivable is substantially mitigated by the Company’s evaluation process, relatively short collection terms, and the high level of creditworthiness of its customers. The Company continually monitors the compliance of its customers with the Company’s payment terms, but generally requires no collateral. The Company had no concentrations greater than 10% of the Company’s net accounts receivable as of March 31, 2022 or December 31, 2021. The Company had no single customer that comprised more than 10% of the Company's total revenues for the three months ended March 31, 2022 or 2021.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Inventory	Inventory Inventory consists of the following as of: March 31, 2022 December 31, 2021 (unaudited) Raw materials $ 3,972 $ 3,442 Work in progress 1,195 965 Finished goods 8,084 7,559 Total inventory $ 13,251 $ 11,966 Finished goods included $94 of consigned inventory at March 31, 2022.

Property, Equipment and Right-o

Property, Equipment and Right-of-Use Assets	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Property, Equipment and Right-of-Use Assets	Property, Equipment and Right-of-Use Assets Property, equipment and right-of-use assets consists of the following: Depreciable Lives March 31, 2022 December 31, 2021 (unaudited) Equipment 5 years $ 7,747 $ 7,472 Right-of-use assets 1-8 years 3,554 3,459 Furniture, fixtures and tooling 4-8 years 1,901 1,855 Computer hardware 3-5 years 1,560 1,444 Leasehold improvements 3-7 years 2,018 2,059 Construction in process 635 483 17,415 16,772 Less accumulated depreciation (11,647) (11,179) Property, equipment and right-of-use assets, net $ 5,768 $ 5,593 The Company recorded depreciation expense of $284 and $429 for the three months ended March 31, 2022 and 2021, respectively. There were no impairment charges for the three months ended March 31, 2022 or 2021. The Company has operating leases for office space in Texas, the United Kingdom, and Italy, and for the manufacturing facility in Costa Rica. The Company also has various operating lease agreements for vehicles. As of March 31, 2022, the maturities of the Company’s operating lease liabilities are as follows: 2022 $ 628 2023 546 2024 449 2025 404 2026 416 Thereafter 756 Total lease payments 3,199 Less imputed interest (686) Total operating lease liabilities $ 2,513 Operating lease liabilities of $578 are included in accrued expenses long-term liabilities

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Accrued Expenses	Accrued Expenses Accrued expenses consists of the following as of: March 31, 2022 December 31, 2021 (unaudited) Accrued employee compensation and expenses $ 4,006 $ 6,569 Accrued professional service fees 765 656 Lease liability 578 587 Accrued taxes 779 437 Accrued interest 307 613 Accrued returns and rebates 93 106 Other 1,028 934 Total accrued expenses $ 7,556 $ 9,902

Long-Term Debt

Long-Term Debt	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt Long-term debt consists of the following as of: March 31, 2022 December 31, 2021 (unaudited) Term loan facility $ 35,000 $ 35,000 Deferred interest 64 6 Deferred financing costs (1,470) (1,533) Long-term debt $ 33,594 $ 33,473 Term Loan Facility In December 2021, the Company entered into a term loan facility with Innovatus Capital Partners, LLC (“Innovatus”) to borrow up to $100,000 (the “Term Loans”) and drew the Term A Loan of $35,000. The Company is eligible to draw the Term B Loan of $15,000 between July 1, 2023 and December 31, 2023 and the Term C Loan of $25,000 between July 1, 2024 and December 31, 2024, in each case upon the achievement of certain minimum revenue thresholds. The Company is eligible to draw the Term D Loan of $25,000 to finance certain approved acquisitions between June 30, 2022 and June 30, 2024. The Term Loans mature on December 21, 2027, with principal payments beginning February 1, 2027, and bear interest at the greater of the Wall Street Journal Prime Rate or 3.25%, plus 4.0%. Principal payments are due on a straight-line basis after the interest-only period concludes. An additional 4.0% of the outstanding amount will be due at the end of the loan term. Prior to December 21, 2025, Innovatus will have the right to make a one-time election to convert up to 10.0% of the outstanding aggregate principal amount of the term loans into shares of common stock of the Company at a price per share equal to $11.50. The Term Loans include customary affirmative covenants and negative covenants. Additionally, it contains a minimum liquidity covenant, tested on a maintenance basis, and a minimum revenue covenant tested quarterly commencing the earlier of December 31, 2023 or the funding date of the Term B loan. The Company used $35,000 of the proceeds of the Term A Loan to repay the previous senior secured credit agreement in full, including interest. Interest expense on the Company’s long-term debt was $750 and $1,058 for the three months ended March 31, 2022 and 2021, respectively. Principal payments of the Company’s long-term debt are as follows: 2022 - 2026 $ — Thereafter 35,000 $ 35,000

Convertible Debt

Convertible Debt	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Convertible Debt	Convertible Debt Convertible debt consists of the following as of: March 31, 2022 December 31, 2021 (unaudited) Convertible debt $ 20,446 $ 20,446 Deferred financing costs (883) (933) Total convertible debt $ 19,563 $ 19,513 In August 2019, the Company issued $20,000 aggregate principal amount of 6.0% convertible senior debentures (the “Convertible Debt”), primarily to existing stockholders and officers of the Company. Interest on the Convertible Debt is payable semi-annually in shares of the Company’s common stock on January 1 and July 1 of each year at a rate of 6.0% per year. The number of shares of common stock required to settle the amount of interest payable will be based on the volume-weighted average price (“VWAP”) of the Company’s common stock for the 10 consecutive trading days immediately preceding the applicable interest payment date. However, in the event that the trailing 10-trading day VWAP of the Company’s common stock is less than $2.50 per share, interest accrued and payable for the applicable interest payment period will accrete to the principal amount then outstanding. The Convertible Debt will mature on August 12, 2026 unless earlier converted or repaid in accordance with its terms. The Company issued 75,780 shares of the Company’s common stock to holders of the Convertible Debt in January 2022 in fulfillment of accrued interest as of December 31, 2021. As of March 31, 2022, accrued interest on the Convertible Debt is $307. The Convertible Debt converts, at the option of the holders, into shares of the Company’s common stock at an initial conversion price of $3.25 per share, subject to adjustment. If the VWAP of the Company’s common stock has been at least $9.75 (subject to adjustment) for at least 20 trading days during any 30 consecutive trading day period, the Company may force the conversion of all or any part of the outstanding principal amount of the Convertible Debt, accrued and unpaid interest and any other amounts then owing, subject to certain conditions. Interest expense on the Convertible Debt was $357 for each of the three months ended March 31, 2022 and 2021.

Long-Term Liabilities

Long-Term Liabilities	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Long-Term Liabilities	Long-Term LiabilitiesIncluded in other long-term liabilities as of March 31, 2022 was $938 for the estimated non-current portion of the exit fee obligation to Solar Capital Ltd., our previous lender, which was reclassified from long-term debt in December 2021. The Company remains obligated to pay $1,925 upon the earlier to occur of (i) certain exit events specified in the Solar Term Facility or (ii) the Company’s achievement of trailing twelve-month revenue of $100,000. Interest expense on this long-term liability was $122 for the three months ended March 31, 2022.

Warrants

Warrants	3 Months Ended
	Mar. 31, 2022
Other Liabilities Disclosure [Abstract]
Warrants	Warrants Warrants consist of the following as of March 31, 2022: Warrant Expiration Date Number of shares Exercise price per share No expiration 13,293,594 $ 0.001 During the three months ended March 31, 2022, pre-funded warrants were exercised into 450,842 shares of common stock and 163,915 warrants expired.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation A summary of the stock option activity as of March 31, 2022 is presented below. Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Options outstanding, December 31, 2021 3,482,883 $ 5.04 8.0 years $ 12,307 Options granted 176,861 5.63 Options exercised (8,216) 3.84 Options forfeited (57,592) 3.59 Options outstanding, vested and expected to vest, March 31, 2022 3,593,936 $ 5.10 7.6 years $ 5,062 Options exercisable 1,834,282 $ 4.71 6.5 years $ 3,522 Shares subject to awards granted under the 2017 Plan which expire, are repurchased, or are canceled or forfeited will again become available for issuance under the 2017 Plan. The shares available will not be reduced by awards settled in cash or by shares withheld to satisfy tax withholding obligations. Only the net number of shares issued upon the exercise of options by means of a net exercise will be deducted from the shares available under the 2017 Plan. The fair value of stock option grants has been estimated at the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions: Three Months Ended Three Months Ended Risk free interest rate 1.9% 1.0% Expected dividend yield —% —% Estimated volatility 81.6% 81.0% Expected life 6.1 years 6.1 years The aggregate intrinsic value in the tables above represents the total pre-tax value of the options shown, calculated as the difference between the Company’s closing stock price on March 31, 2022 and the exercise prices of the options shown, multiplied by the number of in-the money options. This is the aggregate amount that would have been received by the option holders if they had all exercised their options on March 31, 2022 and sold the shares thereby received at the closing price of the Company’s common stock on that date. This amount changes based on the closing price of the Company’s common stock. Additional information regarding options is as follows: Three Months Ended Three Months Ended Weighted-average grant date fair value of options granted during the period $ 3.96 $ 4.12 Aggregate intrinsic value of options exercised during the period $ 21 $ 57 Unrecognized compensation expense related to unvested options was approximately $6,005 at March 31, 2022, with a weighted average remaining amortization period of 2.9 years. A summary of the restricted stock unit activity, including performance-based stock units, under the Company’s Equity Plans as of March 31, 2022 is presented below. Units Weighted Average Grant Date Fair Value Aggregate Intrinsic Value Restricted stock units outstanding, December 31, 2021 1,194,432 $ 5.67 $ 10,069 Restricted stock units granted 996,929 5.63 Restricted stock units released (21,718) 6.02 Restricted stock units forfeited (66,355) 3.90 Restricted stock units outstanding, March 31, 2022 2,103,288 $ 5.70 $ 12,725 In March 2021, the Company awarded 707,278 performance-based restricted stock units to the Company’s chief executive officer in connection with the commencement of his employment. The performance-based restricted stock units vest in four equal tranches upon the achievement of revenue for the trailing four quarters equal to $50,000, $65,000, $80,000, and $95,000. The revenue milestone for the first and second tranche was achieved as of June 30, 2021 and March 31, 2022, respectively.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The provision for income taxes for the three months ended March 31, 2022 and 2021 primarily consists of foreign income taxes. The Company has established a valuation allowance due to uncertainties regarding the realization of deferred tax assets based on the Company’s lack of earnings history and potential limitations pursuant to changes in ownership under Internal Revenue Code Section 382. As of March 31, 2022, the Company has no unrecognized tax benefits or accrued interest or penalties associated with uncertain tax positions.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share The basic and diluted net loss per common share presented in the condensed consolidated statements of operations and comprehensive loss is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Potentially dilutive shares, which include warrants for the purchase of common stock, convertible debt, restricted stock units, including performance-based stock units, and options outstanding under the Company’s equity incentive plans, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. Potentially dilutive securities that are not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares on a weighted-average basis): Three Months Ended March 31, 2022 2021 Warrants for common stock 13,293,594 15,617,335 Convertible debt 6,315,988 6,349,515 Common stock options 3,483,889 3,137,230 Restricted stock units 1,491,016 843,962 24,584,487 25,948,042

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The carrying amounts of the Company’s financial instruments, which primarily include cash, cash equivalents, and restricted cash, accounts receivable, accounts payable and accrued expenses, approximate their fair values due to their short maturities. The fair value of the Company’s long-term debt and Convertible Debt is estimated by management to approximate $35,000 and $20,400, respectively at March 31, 2022. Management’s estimates are based on comparisons of the characteristics of the Company's obligations, comparable ranges of interest rates on recently issued debt, and maturity. Such valuation inputs are considered a Level 3 measurement in the fair value valuation hierarchy. The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices in active markets; Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

Segment and Geographic Informat

Segment and Geographic Information	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Segment and Geographic Information	Segment and Geographic Information Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company globally manages the business within one reportable segment. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance. Product sales by product group and geographic market, based on the location of the customer, whether the U.S. or outside the U.S. (“OUS”) for the periods shown were as follows: Three Months Ended March 31, 2022 Three Months Ended March 31, 2021 (unaudited) U.S. OUS Total Revenues % Total Revenues U.S. OUS Total Revenues % Total Revenues ESS $ 7,220 $ 3,511 $ 10,731 64.4 % $ 5,395 $ 3,244 $ 8,639 62.4 % IGB 2,064 3,667 5,731 34.4 % 1,470 3,493 4,963 35.8 % Other 197 3 200 1.2 % 242 13 255 1.8 % Total revenues $ 9,481 $ 7,181 $ 16,662 100.0 % $ 7,107 $ 6,750 $ 13,857 100.0 % % Total revenues 56.9 % 43.1 % 51.3 % 48.7 % Total distributor sales were 48.9% and 43.7% of total OUS revenues for the three months ended March 31, 2022 and 2021, respectively. Sales in the next largest individual country outside the U.S. were 5.1% of total revenues for the three months ended March 31, 2022 compared to 6.8% for the three months ended March 31, 2021. The following table represents property, equipment and right-of-use assets based on the physical location of the asset: March 31, 2022 December 31, 2021 (unaudited) U.S. $ 2,116 $ 1,855 Costa Rica 3,357 3,436 Other 295 302 Total property, equipment and right-of-use assets, net $ 5,768 $ 5,593

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Organization and Business Description	Apollo Endosurgery, Inc. is a Delaware corporation with both domestic and foreign wholly-owned subsidiaries. Throughout these Notes, “Apollo” and the “Company” refer to Apollo Endosurgery, Inc. and its consolidated subsidiaries. Apollo is a medical technology company primarily focused on the development of next-generation, less invasive medical devices to advance gastrointestinal therapeutic endoscopy. The Company develops and distributes devices that are used by surgeons and gastroenterologists for a variety of procedures related to gastrointestinal conditions including closure of gastrointestinal defects, managing gastrointestinal complications and the treatment of obesity. The Company’s core products include the OverStitch® Endoscopic Suturing System, the OverStitch Sx® Endoscopic Suturing System, X-Tack® Endoscopic HeliX Tacking System (collectively “ESS”) and the ORBERA® Intragastric Balloon (“IGB”). All devices are regulated by the U.S. Food and Drug Administration (the “FDA”) or an equivalent regulatory body outside the U.S. The Company has offices in the United Kingdom and Italy that oversee commercial activities outside the U.S. and a products manufacturing facility in Costa Rica. All other activities are managed and operated from facilities in Austin, Texas.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2020, Accounting Standards Update (“ASU”) No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity was issued, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. This ASU will become effective for the Company on January 1, 2024 and is not expected to have a material impact on the consolidated financial statements. In May 2021, ASU No. 2021-04, Issuer’s Accounting for Certain Modifications of Exchanges of Freestanding Equity-Classified Written Call Options
Net Loss Per Share	The basic and diluted net loss per common share presented in the condensed consolidated statements of operations and comprehensive loss is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Potentially dilutive shares, which include warrants for the purchase of common stock, convertible debt, restricted stock units, including performance-based stock units, and options outstanding under the Company’s equity incentive plans, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consists of the following as of: March 31, 2022 December 31, 2021 (unaudited) Raw materials $ 3,972 $ 3,442 Work in progress 1,195 965 Finished goods 8,084 7,559 Total inventory $ 13,251 $ 11,966

Property, Equipment and Right_2

Property, Equipment and Right-of-Use Assets (Tables)	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property, equipment and right-of-use assets consists of the following: Depreciable Lives March 31, 2022 December 31, 2021 (unaudited) Equipment 5 years $ 7,747 $ 7,472 Right-of-use assets 1-8 years 3,554 3,459 Furniture, fixtures and tooling 4-8 years 1,901 1,855 Computer hardware 3-5 years 1,560 1,444 Leasehold improvements 3-7 years 2,018 2,059 Construction in process 635 483 17,415 16,772 Less accumulated depreciation (11,647) (11,179) Property, equipment and right-of-use assets, net $ 5,768 $ 5,593
Operating Lease Maturity	As of March 31, 2022, the maturities of the Company’s operating lease liabilities are as follows: 2022 $ 628 2023 546 2024 449 2025 404 2026 416 Thereafter 756 Total lease payments 3,199 Less imputed interest (686) Total operating lease liabilities $ 2,513

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consists of the following as of: March 31, 2022 December 31, 2021 (unaudited) Accrued employee compensation and expenses $ 4,006 $ 6,569 Accrued professional service fees 765 656 Lease liability 578 587 Accrued taxes 779 437 Accrued interest 307 613 Accrued returns and rebates 93 106 Other 1,028 934 Total accrued expenses $ 7,556 $ 9,902

Long-Term Debt (Tables)

Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Schedule of Long-term Debt	Long-term debt consists of the following as of: March 31, 2022 December 31, 2021 (unaudited) Term loan facility $ 35,000 $ 35,000 Deferred interest 64 6 Deferred financing costs (1,470) (1,533) Long-term debt $ 33,594 $ 33,473
Schedule of Maturities of Long-term Debt	Principal payments of the Company’s long-term debt are as follows: 2022 - 2026 $ — Thereafter 35,000 $ 35,000

Convertible Debt (Tables)

Convertible Debt (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Schedule of Convertible Debt	Convertible debt consists of the following as of: March 31, 2022 December 31, 2021 (unaudited) Convertible debt $ 20,446 $ 20,446 Deferred financing costs (883) (933) Total convertible debt $ 19,563 $ 19,513

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Mar. 31, 2022
Other Liabilities Disclosure [Abstract]
Schedule of Warrants	Warrants consist of the following as of March 31, 2022: Warrant Expiration Date Number of shares Exercise price per share No expiration 13,293,594 $ 0.001

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Schedule of Stock Option Activity	A summary of the stock option activity as of March 31, 2022 is presented below. Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Options outstanding, December 31, 2021 3,482,883 $ 5.04 8.0 years $ 12,307 Options granted 176,861 5.63 Options exercised (8,216) 3.84 Options forfeited (57,592) 3.59 Options outstanding, vested and expected to vest, March 31, 2022 3,593,936 $ 5.10 7.6 years $ 5,062 Options exercisable 1,834,282 $ 4.71 6.5 years $ 3,522
Schedule of Stock Options, Valuation Assumptions	The fair value of stock option grants has been estimated at the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions: Three Months Ended Three Months Ended Risk free interest rate 1.9% 1.0% Expected dividend yield —% —% Estimated volatility 81.6% 81.0% Expected life 6.1 years 6.1 years
Schedule of Other Stock Option Information	Additional information regarding options is as follows: Three Months Ended Three Months Ended Weighted-average grant date fair value of options granted during the period $ 3.96 $ 4.12 Aggregate intrinsic value of options exercised during the period $ 21 $ 57
Schedule of Restricted Stock Unit Activity	A summary of the restricted stock unit activity, including performance-based stock units, under the Company’s Equity Plans as of March 31, 2022 is presented below. Units Weighted Average Grant Date Fair Value Aggregate Intrinsic Value Restricted stock units outstanding, December 31, 2021 1,194,432 $ 5.67 $ 10,069 Restricted stock units granted 996,929 5.63 Restricted stock units released (21,718) 6.02 Restricted stock units forfeited (66,355) 3.90 Restricted stock units outstanding, March 31, 2022 2,103,288 $ 5.70 $ 12,725

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Diluted Loss Per Share	Potentially dilutive securities that are not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares on a weighted-average basis): Three Months Ended March 31, 2022 2021 Warrants for common stock 13,293,594 15,617,335 Convertible debt 6,315,988 6,349,515 Common stock options 3,483,889 3,137,230 Restricted stock units 1,491,016 843,962 24,584,487 25,948,042

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Schedule of Product Sales by Product Group and Geographic Market	Product sales by product group and geographic market, based on the location of the customer, whether the U.S. or outside the U.S. (“OUS”) for the periods shown were as follows: Three Months Ended March 31, 2022 Three Months Ended March 31, 2021 (unaudited) U.S. OUS Total Revenues % Total Revenues U.S. OUS Total Revenues % Total Revenues ESS $ 7,220 $ 3,511 $ 10,731 64.4 % $ 5,395 $ 3,244 $ 8,639 62.4 % IGB 2,064 3,667 5,731 34.4 % 1,470 3,493 4,963 35.8 % Other 197 3 200 1.2 % 242 13 255 1.8 % Total revenues $ 9,481 $ 7,181 $ 16,662 100.0 % $ 7,107 $ 6,750 $ 13,857 100.0 % % Total revenues 56.9 % 43.1 % 51.3 % 48.7 %
Schedule of Long-Lived Assets by Geographic Area	The following table represents property, equipment and right-of-use assets based on the physical location of the asset: March 31, 2022 December 31, 2021 (unaudited) U.S. $ 2,116 $ 1,855 Costa Rica 3,357 3,436 Other 295 302 Total property, equipment and right-of-use assets, net $ 5,768 $ 5,593

Concentrations (Details)

Concentrations (Details) $ in Thousands	Mar. 31, 2022USD ($)bank	Dec. 31, 2021USD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Risks and Uncertainties [Abstract]
Number of banks | bank	4
Cash and cash equivalents and restricted cash | $	$ 82,738	$ 91,812	$ 32,648	$ 37,200

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 3,972	$ 3,442
Work in progress	1,195	965
Finished goods	8,084	7,559
Total inventory	13,251	$ 11,966
Consigned inventory	$ 94

Property, Equipment and Right_3

Property, Equipment and Right-of-Use Assets (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Right-of-use assets	$ 3,554,000		$ 3,459,000
Property and equipment, gross	17,415,000		16,772,000
Less accumulated depreciation	(11,647,000)		(11,179,000)
Property, equipment and right-of-use assets, net	5,768,000		5,593,000
Depreciation	284,000	$ 429,000
Impairment charges	$ 0	$ 0
Minimum
Property, Plant and Equipment [Line Items]
Depreciable lives, right of use assets	1 year
Maximum
Property, Plant and Equipment [Line Items]
Depreciable lives, right of use assets	8 years
Equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 7,747,000		7,472,000
Depreciable Lives	5 years
Furniture, fixtures and tooling
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,901,000		1,855,000
Furniture, fixtures and tooling | Minimum
Property, Plant and Equipment [Line Items]
Depreciable Lives	4 years
Furniture, fixtures and tooling | Maximum
Property, Plant and Equipment [Line Items]
Depreciable Lives	8 years
Computer hardware
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,560,000		1,444,000
Computer hardware | Minimum
Property, Plant and Equipment [Line Items]
Depreciable Lives	3 years
Computer hardware | Maximum
Property, Plant and Equipment [Line Items]
Depreciable Lives	5 years
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 2,018,000		2,059,000
Leasehold improvements | Minimum
Property, Plant and Equipment [Line Items]
Depreciable Lives	3 years
Leasehold improvements | Maximum
Property, Plant and Equipment [Line Items]
Depreciable Lives	7 years
Construction in process
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 635,000		$ 483,000

Property, Equipment and Right_4

Property, Equipment and Right-of-Use Assets (Lease Maturity) (Details) $ in Thousands	Mar. 31, 2022USD ($)
Property, Plant and Equipment [Abstract]
2022	$ 628
2023	546
2024	449
2025	404
2026	416
Thereafter	756
Total lease payments	3,199
Less imputed interest	(686)
Total operating lease liabilities	$ 2,513

Property, Equipment and Right_5

Property, Equipment and Right-of-Use Assets (Lease Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Operating lease, current	$ 578		$ 587
Operating lease, current, financial statement location	Accrued expenses
Operating lease, noncurrent	$ 1,935
Operating lease, noncurrent, financial statement location	Long-term liabilities
Cash paid within operating cash flows for operating leases	$ 255	$ 267
Weighted average remaining lease term	4 years 6 months
Weighted average discount rate, percent	8.90%
Lease term	1 year

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued employee compensation and expenses	$ 4,006	$ 6,569
Accrued professional service fees	765	656
Lease liability	578	587
Accrued taxes	779	437
Accrued interest	307	613
Accrued returns and rebates	93	106
Other	1,028	934
Total accrued expenses	$ 7,556	$ 9,902

Long-Term Debt (Schedule of Lon

Long-Term Debt (Schedule of Long-term Debt) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Deferred financing costs	$ (1,470)	$ (1,533)
Long-term debt	33,594	33,473
Deferred interest
Debt Instrument [Line Items]
Long-term debt	64	6
Term loan facility | Term loan facility
Debt Instrument [Line Items]
Long-term debt	$ 35,000	$ 35,000

Long-Term Debt (Narrative) (Det

Long-Term Debt (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended
	Dec. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Debt Instrument [Line Items]
Line of credit		$ 35,000
Interest expense		$ 750	$ 1,058
Term loan facility
Debt Instrument [Line Items]
Percent of instrument converted	10.00%
Conversion price (USD per share)	$ 11.50
Term loan facility | Term loan facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 100
Interest rate	3.25%
Percent of outstanding amount due	4.00%
Term loan facility | Term loan facility | Prime Rate
Debt Instrument [Line Items]
Basis spread on variable rate	4.00%
Term loan facility | Term A Loan
Debt Instrument [Line Items]
Proceeds from term loan	$ 35,000
Term loan facility | Term B Loan
Debt Instrument [Line Items]
Line of credit	15
Term loan facility | Term C Loan
Debt Instrument [Line Items]
Line of credit	25
Term loan facility | Term D Loan
Debt Instrument [Line Items]
Line of credit	$ 25

Long-Term Debt (Schedule of Mat

Long-Term Debt (Schedule of Maturity of Long-term Debt) (Details) $ in Thousands	Mar. 31, 2022USD ($)
Debt Disclosure [Abstract]
2022	$ 0
2023	0
2024	0
2025	0
2026	0
Thereafter	35,000
Line of credit	$ 35,000

Convertible Debt (Schedule of C

Convertible Debt (Schedule of Convertible Debt) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Deferred financing costs	$ (1,470)	$ (1,533)
Long-term debt	33,594	33,473
Convertible debt
Debt Instrument [Line Items]
Convertible debt	20,446	20,446
Deferred financing costs	(883)	(933)
Long-term debt	$ 19,563	$ 19,513

Convertible Debt (Narrative) (D

Convertible Debt (Narrative) (Details) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended
	Jan. 31, 2021shares	Aug. 31, 2019USD ($)d$ / shares	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)
Debt Instrument [Line Items]
Accrued interest			$ 307		$ 613
Interest expense			750	$ 1,058
Convertible debt
Debt Instrument [Line Items]
Proceeds from convertible debt		$ 20,000
Interest rate		6.00%
Stock price (USD per share) | $ / shares		$ 2.50
Conversion of convertible debt (in shares) | shares	75,780
Interest expense			$ 357	$ 357
Convertible debt | Conversion Ratio Less Than 2.50
Debt Instrument [Line Items]
Consecutive trading days (in days) | d		10
Convertible debt | Conversion Ratio Of 3.25
Debt Instrument [Line Items]
Consecutive trading days (in days) | d		30
Conversion price (USD per share) | $ / shares		$ 3.25
Stock price trigger (USD per share) | $ / shares		$ 9.75
Trading days (in days) | d		20

Long-Term Liabilities (Details)

Long-Term Liabilities (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Debt Instrument [Line Items]
Exit fee liability, noncurrent	$ 938
Interest expense on long-term liability	122
Solar Term Loan Facility
Debt Instrument [Line Items]
Liabilities, noncurrent	1,925
Trailing twelve month revenue	$ 100,000

Warrants (Details)

Warrants (Details) - No expiration	Mar. 31, 2022$ / sharesshares
Class of Warrant or Right [Line Items]
Total number of warrants outstanding (in shares) | shares	13,293,594
Exercise price (USD per share) | $ / shares	$ 0.001

Warrants - Narrative (Details)

Warrants - Narrative (Details)	3 Months Ended
	Mar. 31, 2022shares
Class of Warrant or Right [Line Items]
Expirations (in shares)	163,915
Warrant
Class of Warrant or Right [Line Items]
Issued warrants to purchase shares, number of shares (in shares)	450,842

Stock-Based Compensation (Stock

Stock-Based Compensation (Stock Option Activity) (Details) - Stock Option - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Options
Options outstanding, beginning balance (in shares)		3,482,883
Options granted (in shares)	176,861
Options exercised (in shares)	(8,216)
Options forfeited (in shares)	(57,592)
Options vested and expected to vest (in shares)	3,593,936
Options exercisable (in shares)	1,834,282
Weighted Average Exercise Price
Weighted average exercise price, beginning balance (in USD per share)		$ 5.04
Options granted (in USD per share)	$ 5.63
Options exercised (in USD per share)	3.84
Options forfeited (in USD per share)	3.59
Options vested and expected to vest (in USD per share)	5.10
Options exercisable (in USD per share)	$ 4.71
Weighted Average Remaining Contractual Term
Weighted Average Remaining Contractual Term		8 years
Options vested and expected to vest	7 years 7 months 6 days
Options exercisable	6 years 6 months
Aggregate Intrinsic Value
Aggregate intrinsic value		$ 12,307
Options vested and expected to vest	$ 5,062
Options exercisable	$ 3,522

Stock-Based Compensation (Fair

Stock-Based Compensation (Fair Value of Stock Options) (Details) - Stock Option	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.90%	1.00%
Expected dividend yield	0.00%	0.00%
Estimated volatility	81.60%	81.00%
Expected life	6 years 1 month 6 days	6 years 1 month 6 days

Stock-Based Compensation (Addit

Stock-Based Compensation (Additional Information) (Details) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended
	Aug. 31, 2021	Mar. 31, 2021USD ($)trancheshares	Mar. 31, 2022USD ($)$ / sharesshares	Mar. 31, 2021USD ($)$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense related to unvested options			$ 6,005
Remaining amortization period			2 years 10 months 24 days
Common stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value of options granted during period (in USD per share) | $ / shares			$ 3.96	$ 4.12
Aggregate intrinsic value of options exercised during the period			$ 21	$ 57
Options granted (in shares) | shares			176,861
Common stock options | Chief Financial Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	25.00%
Restricted stock units and Performance shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining amortization period			3 years 2 months 12 days
Restricted stock units and Performance shares | Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (in shares) | shares		707,278
Number of tranches | tranche		4
Restricted stock units and Performance shares | Chief Executive Officer | Quarter one
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amount vested		$ 50,000
Restricted stock units and Performance shares | Chief Executive Officer | Quarter two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amount vested		65,000
Restricted stock units and Performance shares | Chief Executive Officer | Quarter three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amount vested		80,000
Restricted stock units and Performance shares | Chief Executive Officer | Quarter four
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amount vested		$ 95,000
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense related to unvested restricted stock units			$ 7,054
Performance shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense related to unvested restricted stock units			$ 1,610

Stock-Based Compensation (Restr

Stock-Based Compensation (Restricted Stock Units Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Restricted stock units and Performance shares
Units
Unvested Units (shares)	1,194,432
Restricted stock units and performance stock units granted (shares)	996,929
Unvested Units (shares)	2,103,288
Weighted Average Grant Date Fair Value
Unvested Units (USD per share)	$ 5.67
Restricted stock units and performance stock units granted (USD per share)	5.63
Unvested Units (USD per share)	$ 5.70
Aggregate Intrinsic Value
Aggregate Intrinsic Value	$ 12,725	$ 10,069
Restricted stock units
Units
Restricted stock units vested (shares)	(21,718)
Restricted stock units forfeited (shares)	(66,355)
Weighted Average Grant Date Fair Value
Restricted stock units vested (USD per share)	$ 6.02
Restricted stock units forfeited (USD per share)	$ 3.90

Income Taxes (Details)

Income Taxes (Details)	Mar. 31, 2022USD ($)
Income Tax Disclosure [Abstract]
Unrecognized tax benefits	$ 0
Accrued interest	0
Tax penalties	$ 0

Net Loss Per Share (Details)

Net Loss Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted loss per share (in shares)	24,584,487	25,948,042
Warrants for common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted loss per share (in shares)	13,293,594	15,617,335
Convertible debt
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted loss per share (in shares)	6,315,988	6,349,515
Common stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted loss per share (in shares)	3,483,889	3,137,230
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted loss per share (in shares)	1,491,016	843,962

Fair Value Measurements (Detail

Fair Value Measurements (Details) $ in Thousands	Mar. 31, 2022USD ($)
Fair Value Disclosures [Abstract]
Fair value of long-term debt	$ 35,000
Convertible debt, fair value	$ 20,400

Segment and Geographic Inform_3

Segment and Geographic Information (Segment Information) (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)segment	Mar. 31, 2021USD ($)
Segment Reporting [Abstract]
Number of reportable segments | segment	1
Revenue, Major Customer [Line Items]
Revenues	$ 16,662	$ 13,857
Segment Revenue | Product Risk
Revenue, Major Customer [Line Items]
Percentage of revenue or sales	100.00%	100.00%
U.S.
Revenue, Major Customer [Line Items]
Revenues	$ 9,481	$ 7,107
U.S. | Segment Revenue | Product Risk
Revenue, Major Customer [Line Items]
Percentage of revenue or sales	56.90%	51.30%
OUS
Revenue, Major Customer [Line Items]
Revenues	$ 7,181	$ 6,750
OUS | Segment Revenue | Product Risk
Revenue, Major Customer [Line Items]
Percentage of revenue or sales	43.10%	48.70%
OUS | Segment Revenue | Geographic Concentration Risk
Revenue, Major Customer [Line Items]
Percentage of revenue or sales	5.10%	6.80%
OUS | Distributor Sales | Product Risk
Revenue, Major Customer [Line Items]
Percentage of revenue or sales	48.90%	43.70%
ESS
Revenue, Major Customer [Line Items]
Revenues	$ 10,731	$ 8,639
ESS | Segment Revenue | Product Risk
Revenue, Major Customer [Line Items]
Percentage of revenue or sales	64.40%	62.40%
ESS | U.S.
Revenue, Major Customer [Line Items]
Revenues	$ 7,220	$ 5,395
ESS | OUS
Revenue, Major Customer [Line Items]
Revenues	3,511	3,244
IGB
Revenue, Major Customer [Line Items]
Revenues	$ 5,731	$ 4,963
IGB | Segment Revenue | Product Risk
Revenue, Major Customer [Line Items]
Percentage of revenue or sales	34.40%	35.80%
IGB | U.S.
Revenue, Major Customer [Line Items]
Revenues	$ 2,064	$ 1,470
IGB | OUS
Revenue, Major Customer [Line Items]
Revenues	3,667	3,493
OtherProductsMember
Revenue, Major Customer [Line Items]
Revenues	$ 200	$ 255
OtherProductsMember | Segment Revenue | Product Risk
Revenue, Major Customer [Line Items]
Percentage of revenue or sales	1.20%	1.80%
OtherProductsMember | U.S.
Revenue, Major Customer [Line Items]
Revenues	$ 197	$ 242
OtherProductsMember | OUS
Revenue, Major Customer [Line Items]
Revenues	$ 3	$ 13

Segment and Geographic Inform_4

Segment and Geographic Information (Long-Lived Assets by Geographic Area) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Total property, equipment and right-of-use assets, net	$ 5,768	$ 5,593
U.S.
Revenues from External Customers and Long-Lived Assets [Line Items]
Total property, equipment and right-of-use assets, net	2,116	1,855
Costa Rica
Revenues from External Customers and Long-Lived Assets [Line Items]
Total property, equipment and right-of-use assets, net	3,357	3,436
Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Total property, equipment and right-of-use assets, net	$ 295	$ 302